Nutra Pharma Corporation (NPHC) Initiates 2016 Gro
Post# of 102
Posted On: 02/16/2016 5:53:51 PM
Nutra Pharma Corporation (NPHC) Initiates 2016 Growth Strategy with Key Addition to Management Team
Before the opening bell, Nutra Pharma Corporation (OTCQB: NPHC) announced a key expansion of personnel, naming Thomas W. Northrop as its senior commercial development officer. Northrop is a Fellow of the American College of Healthcare Executives with experience leading hospitals, healthcare networks and physician groups in several regions of the country. He is also a member of Tri-State Capital Partners, LLC, a New York-based management advisory and investment firm offering combined management resources, strategy development and implementation and capital funding expertise to promising businesses. As a member of the Nutra Pharma management team, Northrop will lead new marketing efforts in healthcare, governmental and military entities; aging athletes; and the elderly, as well as playing a key role in the completion of scientifically rigorous pain relief trials in multiple settings.
“The addition of Tom Northrop and Tri-State’s arrival as part of Nutra Pharma’s expanded management team are the first steps in the company’s growth strategy for 2016,” Rik J. Deitsch, chief executive officer of Nutra Pharma, stated in the news release. “Tri-State believes, as we do, that Nutra Pharma has a powerful set of products that effectively combat chronic – often debilitating – pain, without the damaging side effects common to other treatments. We have been working closely over the last few months and they are now committed to helping us achieve our growth goals.”
In 2012, health care providers throughout the United States wrote 259 million prescriptions for opioid painkillers, according to a report by the Centers for Disease Control and Prevention (http://dtn.fm/zqY9A), equating to roughly twice the number of painkiller prescriptions per person written in neighboring Canada. As opioid abuse continues to emerge as a growing cause for concern throughout the country, Nutra Pharma’s innovative pain relief solutions, which are non-opiate, non-narcotic and non-addictive, strategically position the company to address an expansive global market while simultaneously promoting sustainable financial growth.
“With opioid abuse at record levels, and increased recognition of the dangers of misusing acetaminophen and non-steroidal anti-inflammatory drugs (NSAID) like ibuprofen, Nutra Pharma is well positioned to help an enormous global market, and to reap the associated rewards,” added Northrop.
Nutra Pharma is currently marketing both Nyloxin® and Pet Pain-Away in the over-the-counter pain management market. Nyloxin is available as both an oral spray and a topical gel and is specifically formulated to treat back pain, neck pain, headaches, joint pain, migraines, arthritis pain, pain from repetitive stress and neuralgia. Pet Pain-Away is an all-natural, anti-inflammatory analgesic pain relief targeting conditions that cause chronic pain in animals.
The company is also developing treatments for multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy and pain. In a letter to shareholders released in December, Deitsch highlighted Nutra Pharma’s recent progress toward promoting market growth – including the reception of orphan status for RPI-78M for the treatment of pediatric MS and submittal of an additional application for orphan status for the treatment of myasthenia gravis.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Before the opening bell, Nutra Pharma Corporation (OTCQB: NPHC) announced a key expansion of personnel, naming Thomas W. Northrop as its senior commercial development officer. Northrop is a Fellow of the American College of Healthcare Executives with experience leading hospitals, healthcare networks and physician groups in several regions of the country. He is also a member of Tri-State Capital Partners, LLC, a New York-based management advisory and investment firm offering combined management resources, strategy development and implementation and capital funding expertise to promising businesses. As a member of the Nutra Pharma management team, Northrop will lead new marketing efforts in healthcare, governmental and military entities; aging athletes; and the elderly, as well as playing a key role in the completion of scientifically rigorous pain relief trials in multiple settings.
“The addition of Tom Northrop and Tri-State’s arrival as part of Nutra Pharma’s expanded management team are the first steps in the company’s growth strategy for 2016,” Rik J. Deitsch, chief executive officer of Nutra Pharma, stated in the news release. “Tri-State believes, as we do, that Nutra Pharma has a powerful set of products that effectively combat chronic – often debilitating – pain, without the damaging side effects common to other treatments. We have been working closely over the last few months and they are now committed to helping us achieve our growth goals.”
In 2012, health care providers throughout the United States wrote 259 million prescriptions for opioid painkillers, according to a report by the Centers for Disease Control and Prevention (http://dtn.fm/zqY9A), equating to roughly twice the number of painkiller prescriptions per person written in neighboring Canada. As opioid abuse continues to emerge as a growing cause for concern throughout the country, Nutra Pharma’s innovative pain relief solutions, which are non-opiate, non-narcotic and non-addictive, strategically position the company to address an expansive global market while simultaneously promoting sustainable financial growth.
“With opioid abuse at record levels, and increased recognition of the dangers of misusing acetaminophen and non-steroidal anti-inflammatory drugs (NSAID) like ibuprofen, Nutra Pharma is well positioned to help an enormous global market, and to reap the associated rewards,” added Northrop.
Nutra Pharma is currently marketing both Nyloxin® and Pet Pain-Away in the over-the-counter pain management market. Nyloxin is available as both an oral spray and a topical gel and is specifically formulated to treat back pain, neck pain, headaches, joint pain, migraines, arthritis pain, pain from repetitive stress and neuralgia. Pet Pain-Away is an all-natural, anti-inflammatory analgesic pain relief targeting conditions that cause chronic pain in animals.
The company is also developing treatments for multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy and pain. In a letter to shareholders released in December, Deitsch highlighted Nutra Pharma’s recent progress toward promoting market growth – including the reception of orphan status for RPI-78M for the treatment of pediatric MS and submittal of an additional application for orphan status for the treatment of myasthenia gravis.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)Nutra Pharma Corp. (NPHC) Stock Research Links
Scroll down for more posts ▼